ML20216H913

From kanterella
Jump to navigation Jump to search
Staff Requirements Memo Re SECY-97-177, Final Rulemaking Plan:Rev of Dose Limit for Members of Public Exposed to Hospitalized Patients (10CFR20 & 10CFR35)
ML20216H913
Person / Time
Issue date: 09/09/1997
From: Hoyle J
NRC OFFICE OF THE SECRETARY (SECY)
To: Callan L
NRC OFFICE OF THE EXECUTIVE DIRECTOR FOR OPERATIONS (EDO)
References
REF-10CFR9.7 SECY-97-177-C, NUDOCS 9709170109
Download: ML20216H913 (2)


Text

/,,,*%

a................

.<,,aa UNITED STATES g * '), ( ,4 '~

NUCLEAR REGULATORY COMMISSIOp RELEASEDTO THE PDR WASHINGTON. D.C. 20556-0001 4-o if3!0I init'als September 9, 1997 OFFICf 0F THE.

SECRETARY MEMORANDUM TO:

L. Joseph Callan Executive Director for Operations

+ % w gr/

FROM:

John C. Hoyle FINAL

SUBJECT:

STAFF REQUIREMENTS - SECY-97-177 RULEMAKING PLAN:

REVISION OF DOSE LIMIT FOR

'iEMBERS OF THE PUBLIC EXPOSED TO HOSPITALIFED PATIENTS (10 CFR PART 20 AND 35)

This is to advise yru that the Commission has not objected to the staff's proposed rulemaking plan as described in Option 3 subject to the following comments.

The staff should justify on a public health and safety benefit basis the requirement for licensee documentation that it has provided instruction to the family members and that it has obtained. informed consent from the family members in light of the fact that documentation of instruction to and informed consent from, released patients is not required under 10 CFR 35,75(a) or (b).

If retained, this recordkeeping issue should be specifically discussed in the Federal Reaister notice accompanying the croposed rule and the staff should seek public comments and views on the need for these recordkeeping requirements.

Should the consent form eventually be used, the staff should coordinate with ACMUI to draft a " plain English" informed consent form.

Any public notice of this rule should make it clear that family members admitted to the room of a patient treated with permanent f /-

implants, or administered radiopharmaceutical therapy, and I

subsequently released under 10 CFR 35.75 may, as a result of this h

rulemaking, actually receive a total dose-of 1.0 rem.

I The new compatibility categories descdbed in'the " Policy for h

3 Adequacy and Compatibility of Agreement State Programs" snould be reflected in this rulemaking-plan.

IP h g fd SECY NOTE:

THIS SRM AND SECY-97-177 WILL BE MADE PUBLICLY AVAILABLE 5 WORKING DAYS FROM THE DATE OF THIS SRM.

@,1 fon OcN bl5lllIIl$llklfl PT9.7 PDR

l'

. cc i - Chairman Jackson Commissioner Dicus Commissioner Diaz commissioner McGaffigan OGC CIO CFO OCA OIG Office Directors, Regions, ACRS, ACNW, ASLBP (via E-Mail)

PDR DCS

.